{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:02:03Z","timestamp":1792836123625,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jacc.2022.01.029","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T14:54:45Z","timestamp":1647874485000},"page":"1129-1137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart\u00a0Failure and Preserved Ejection\u00a0Fraction"],"prefix":"10.1016","volume":"79","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schueler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Steubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jacc.2022.01.029_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2022.01.029_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jacc.2022.01.029_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2022.01.029_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacc.2022.01.029_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacc.2022.01.029_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ejhf.326","article-title":"Geographic differences in heart failure trials","volume":"17","author":"Ferreira","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.jacc.2022.01.029_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacc.2022.01.029_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacc.2022.01.029_bib9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection\u00a0fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacc.2022.01.029_bib10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2022.01.029_bib11","first-page":"254","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"10","key":"10.1016\/j.jacc.2022.01.029_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.jacc.2022.01.029_bib13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2022.01.029_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jacc.2022.01.029_bib15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: the EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.jacc.2022.01.029_bib16","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722002492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722002492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:48:18Z","timestamp":1760017698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722002492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0735109722002492"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.01.029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741852989.793592285","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.741852989.793593046","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart\u00a0Failure and Preserved Ejection\u00a0Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}